{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107617","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.603011+00:00","generated_at":"2026-05-17T13:57:10.374223+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ARS Pharma Q2 revenue $15.7M, neffy volume +180% QoQ, net loss $44.9M","bullets":["Total revenue $15.7M, including $12.8M neffy U.S. net product revenue and $2.6M milestone from ALK.","Net loss of $44.9M ($0.46/sh); SG&A $54.3M driven by DTC campaign; cash $240.1M.","neffy weekly script volumes grew ~180% from Q1 end to Q2 end; 93% commercial coverage achieved.","EUR neffy approved in UK and launched in Germany; $5M milestone triggered from ALK.","Phase 2b urticaria trial initiated; topline data expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107617","json":"https://secwatch.observer/filing/0000950170-25-107617.json","markdown":"https://secwatch.observer/filing/0000950170-25-107617.md","text":"https://secwatch.observer/filing/0000950170-25-107617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017025107617/0000950170-25-107617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017025107617/spry-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:10.374223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}